FDA Advisors Recommend Approval Of Taxol for Node-Positive Breast Cancer
In Brief: Justice Department Files Civil Suit To recover $25 Billion From Tobacco
ODAC Actions: Large Subset analysis Of CALGB Study Was Basis for BMS Taxol Application
UFT – Leucovorin Combo Not A Breakthrough, But could Merit Approval, Committee Says
Roferon A Application Marred By Mission Data, Protocol, Compliance
Underpowered Study Of Evacet Dashes Approval Hopes
NCI Programs: Institute Funds 24 DNA Microarray Centers
Trending Stories
- DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy
- In The Headlines: HHS shakeup threatens a legacy of medical breakthroughs
- Brian Druker, developer of Gleevec, eyes a new feat: Setting the Boston Marathon fundraising record
Current record: $507,000. Proceeds to go to LLS as NIH funding is slashed - Amid HHS upheaval, Bhattacharya takes the helm at NIH, Makary at FDA
Meanwhile, NASEM sounds “SOS” for health infrastructure